No Prescription |
 |
 | ||
|
Micardis Plus Generic Telmisartan Hydrochlorothiazide |
|
| ||
No Prescription » Prescription Drugs 11 » Micardis Plus Generic Telmisartan Hydrochlorothiazide This medication is used to treat high blood pressure (hypertension). Lowering high blood pressure helps prevent strokes heart attacks and kidney problems. This medication is a combination of two drugs. Telmisartan works by relaxing blood vessels so blood can flow more easily. Hydrochlorothiazide increases the amount of urine you make removing extra water and salt from your body. Telmisartan belongs to a class of drugs called angiotensin receptor blockers and hydrochlorothiazide is commonly called a "water pill" or diuretic. Buy Micardis Plus Generic Telmisartan Hydrochlorothiazide and other Prescription Drugs 11 products online at Medstore. Buy Online at Medstore - Click Here!
About Micardis Plus Generic Telmisartan Hydrochlorothiazide: Product Type: Prescription Drugs 11 Micardis Plus ( Generic Telmisartan & Hydrochlorothiazide ) Micardis Plus (Generic Telmisartan & Hydrochlorothiazide) Generic Telmisartan & Hydrochlorothiazide 80/12.5mg Generic Telmisartan & Hydrochlorothiazide Micardis Plus
View more Prescription Drugs 11 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
